Making use of the primary tumour

BioEssays

Volumn 25, Issue 1, 2003, Pages 79-86

  Baars, Arnold ^a   Buter, Jan ^a   Pinedo, Herbert M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0037232895     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.10194     Document Type: Review

References (27)

1. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med 2000; 343(5):338-344.
2. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001;19:47-64.
3. Lanzavecchia A, Sallusto F. Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science 2000;290:92-97.
4. O'Donnell MA, Luo Y, Chen X, Szilvasi A, Hunter SE, Clinton SK. Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guerin. J Immunol 1999;163:4246-4252.
5. Greten TF, Jaffee EM. Cancer vaccines. J Clin Oncol 1999;17:1047-1060.
6. Swain SL, Bradley LM, Croft M, Tonkonogy S, Atkins G, Weinberg AD, Duncan DD, Hedrick SM, Dutton RW, Huston G. Helper T-cell subsets; phenotype, function and the role of lymphokines in regulating their development. Immunol Rev 1991;123:115-144.
7. Radvanyi L, Miller RG. Immunology related to cancer. In: Tannock IF, Hill RP, editors, The basic Science of Oncology (3rd ed.). New York: McGraw-Hill; 1998.
8. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
9. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med 2001;344:655-664.
10. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045.
11. Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer 2001;85:1047-1054.
12. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Clin Orthop 1893; 3-11.
13. Rosenberg SA, Rapp HJ. Intralesional immunotherapy of melanoma with BCG. Med Clin North Am 1976;60:419-430.
14. Veronesi U, Adamus J, Aubert C, Bajetta E, Beretta G, Bonadonna G, Bufalino R, Cascinelli N, Cocconi G, Durand J. et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 1982;307:913-916.
15. Marincola FM, White DE, Wise AP, Rosenberg SA. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995;13:1110-1122.
16. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Guiber R, Funke I, Pichlmaier H, Hirche H, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16:1788-1794.
17. de Kleijn EM, Punt CJ. Biological therapy of colorectal cancer. Eur J Cancer 2002;38:1016-1022.
18. Peters LC, Brandhorst JS, Hanna MG Jr. Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res 1979;39:1353-1360.
19. Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999;353:345-350.
20. Hoover HC Jr, Surdyke M, Dangel RB, Peters LC, Hanna MG Jr. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guerin vaccine. Cancer Res 1984;44:1671-1676.
21. Hoover HC Jr, Brandhorst JS, Peters LC, Surdyke MG, Takeshita Y, Madariaga J, Muenz LR, Hanna MG, Jr. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5- year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993;11:390-399.
22. Harris JE, Ryan L, Hoover HC Jr, Stuart RK, Oken MM, Benson AB III, Mansour E, Haller DG, Manola J, Hanna MG, Jr. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol 2000;18:148-157.
23. Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 1994;74(Suppl 1):416-423.
24. Esteva FJ, Hortobagyi GN. Integration of Systemic Chemotherapy in the Management of Primary Breast Cancer. Oncologist 1998;3:300-313.
25. Honkoop AH, Luykx-de Bakker SA, Hoekman K, Meyer S, Meyer OW, Van Groeningen CJ, Van Diest PJ, Boven E, Van der Wall E, Giaccone G, et al. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. Oncologist 1999;4:106-111.
26. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000;191:423-434.
27. Armitage JO. Emerging applications of recombinant human granulocytemacrophage colony-stimulating factor. Blood 1998;92:4491-4508.